[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381868-105":59,"doc-detail-381868-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","gastric-cancer-peritoneal-metastasis-related-signature-predicts-prognosis-and-sensitivity-to-immunotherapy-in-gastric-cancer","Gastric cancer peritoneal metastasis related signature predicts prognosis and sensitivity to immunotherapy in gastric cancer","","Gastric cancer peritoneal metastases (GCPM) drive mortality in gastric cancer, making early detection essential for improving outcomes in advanced disease. Differentially expressed genes from the GSE62254 dataset were used to build a gastric cancer peritoneal metastases signature (GCPMs). The study evaluates GCPMs as a predictor for prognosis, chemotherapy response, and immunotherapy sensitivity, and explores its links to the immune microenvironment and immune escape. Random forest analysis and immunohistochemistry identified key diagnostic genes including SYNPO2, with findings also associated with stromal score and cancer-associated fibroblasts.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gastric-cancer-peritoneal-metastasis-related-signature-predicts-prognosis-and-sensitivity-to-immunotherapy-in-gastric-cancer/381868/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gastric-cancer-peritoneal-metastasis-related-signature-predicts-prognosis-and-sensitivity-to-immunotherapy-in-gastric-cancer/381868.png","ImageObject",300,407,{"name":92,"@type":93},"Franzy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What dataset and method were used to construct the gastric cancer peritoneal metastases signature (GCPMs)?","Question",{"text":113,"@type":114},"Differentially expressed genes were identified from the GSE62254 database to distinguish GCPM from non-GCPM, then used to develop GCPMs. Random forest and immunohistochemistry were used to identify crucial diagnostic genes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does GCPMs relate to prognosis and chemotherapy response in gastric cancer patients?",{"text":118,"@type":114},"Patients with high GCPMs showed a higher likelihood of poor prognosis, while those with low GCPMs appeared more likely to benefit from chemotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"Which gene was identified as most significant for diagnosis, and what did immunohistochemistry suggest?",{"text":122,"@type":114},"SYNPO2 was identified as the gene with the highest significance in diagnosing GCPM. Immunohistochemistry suggested that SYNPO2-positive expression in tumor cells, fibroblasts, and inflammatory cells may be associated with promoting peritoneal metastasis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},381868,1790749676,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Received: 6 April 2023 | Revised: 24 July 2023 | Accepted: 11 August 2023  \nDOI: 10. 1111/jcmm.17922  \nOR I G I NAL ART I C L E  \nGastric cancer peritoneal metastasis related signature predicts prognosis and sensitivity to immunotherapy in gastric cancer  \nYuQin Sun1 | YueQing Chen2 | Wei Zhuang3 | ShunYong Fang1 | QiuXian Chen1 | MingQiao Lian1 | ChenBin Lv1 | JianMing Weng2 | Ran Wei4 | Yao Lin5 | LiSheng Cai1 | QingShui Wang5,6   \n1Department of Gastrointestinal Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China 2Department of Pathology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China 3 Department of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China  \n4Changzhou Key Laboratory of Respiratory Medical Engineering, Institute of Biomedical Engineering and Health Sciences, School of Medical and Health Engineering, Changzhou University, Changzhou, China  \n5Central Laboratory at the Second Affiliated Hospital of Fujian University of Traditional Chinese Medical UniversityMedicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Innovation and Transformation Center, Fujian University of Traditional Chinese Medicine, Fuzhou, China  \n6College of Life Sciences, Fujian Normal University, Fuzhou, China  \nCorrespondence  \nQingShui Wang and Yao Lin, Central Laboratory at the Second Affiliated Hospital of Fujian University of Traditional Chinese Medical UniversityMedicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Innovation and Transformation Center, Fujian University of Traditional Chinese Medicine, Fuzhou 361000, China.  \n[Email:](Email: yaolin@fjtcm.edu.cn)[ yaolin@fjtcm.edu.cn](Email: yaolin@fjtcm.edu.cn) and [wangqingshui@fjnu.edu.cn](wangqingshui@fjnu.edu.cn)  \nLiSheng Cai, Department of Gastrointestinal Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, China.  \nEmail: [1272110762@qq.com](1272110762@qq.com)  \nRan Wei, Changzhou Key Laboratory of Respiratory Medical Engineering, Institute of Biomedical Engineering and Health Sciences, School of Medical and Health Engineering, Changzhou University, Changzhou 213164, China. [Email:](Email: weiran@cczu.edu.cn)[ weiran@cczu.edu.cn](Email: weiran@cczu.edu.cn)  \nAbstract  \nGastric cancer peritoneal metastases (GCPM) is a leading cause of GC-related death. Early detection of GCPM is critical for improving the prognosis of advanced GC. Differentially expressed genes (DEGs) were identified in the GSE62254 database to distinguish between GCPM and non-GCPM. The gastric cancer peritoneal metastases signature (GCPMs) was developed using DEGs. We analysed the effectiveness of GCPMs as indicators for prognosis, chemotherapy, and immune therapy response in GC patients. Subsequently, we analysed the correlation between GCPMs and immune microenvironment as well as immune escape in GC patients. Random forest model and immunohistochemistry was utilized to identify the crucial genes that can aid in the diagnosis of GCPM. We identified five DEGs and utilized their expression to construct GCPMs. Patients with high GCPMs had a higher likelihood of a poor prognosis, while those with low GCPMs appeared to potentially benefit more from chemotherapy. GCPMs were a dependable marker for predicting the response to immunotherapy. Additionally, GCPMs was found to be significantly linked to stromal score and cancer-associated fibroblasts. SYNPO2 has been identified as the gene with the highest significance in the diagnosis of GCPM. Immunohistochemistry suggests that SYNPO2-positive expression in tumour cells, fibroblasts, inflammatory cell maybe associated with promoting peritoneal metastasis in GC. GCPMs have shown to be  \nYuQin Sun, YueQing Chen, Wei Zhuang and ShunYong Fang contributed equally to this ","cbCaioR8dW4MhIFr","https://ap.wps.com/l/cbCaioR8dW4MhIFr","pdf",26142092,13,"English","# Abstract\n## Keywords\n## Introduction","[{\"question\":\"What dataset and method were used to construct the gastric cancer peritoneal metastases signature (GCPMs)?\",\"answer\":\"Differentially expressed genes were identified from the GSE62254 database to distinguish GCPM from non-GCPM, then used to develop GCPMs. Random forest and immunohistochemistry were used to identify crucial diagnostic genes.\"},{\"question\":\"How does GCPMs relate to prognosis and chemotherapy response in gastric cancer patients?\",\"answer\":\"Patients with high GCPMs showed a higher likelihood of poor prognosis, while those with low GCPMs appeared more likely to benefit from chemotherapy.\"},{\"question\":\"Which gene was identified as most significant for diagnosis, and what did immunohistochemistry suggest?\",\"answer\":\"SYNPO2 was identified as the gene with the highest significance in diagnosing GCPM. Immunohistochemistry suggested that SYNPO2-positive expression in tumor cells, fibroblasts, and inflammatory cells may be associated with promoting peritoneal metastasis.\"}]","Gastric cancer peritoneal metastasis related signature predicts prognosis and sensitivity to immunotherapy in gastric cancer | PDF",1790247523,33]